6N79

Structure of the human JAK1 kinase domain with compound 20


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.224 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Zak, M.Hanan, E.J.Lupardus, P.Brown, D.G.Robinson, C.Siu, M.Lyssikatos, J.P.Romero, F.A.Zhao, G.Kellar, T.Mendonca, R.Ray, N.C.Goodacre, S.C.Crackett, P.H.McLean, N.Hurley, C.A.Yuen, P.W.Cheng, Y.X.Liu, X.Liimatta, M.Kohli, P.B.Nonomiya, J.Salmon, G.Buckley, G.Lloyd, J.Gibbons, P.Ghilardi, N.Kenny, J.R.Johnson, A.

(2019) Bioorg.Med.Chem.Lett. 29: 1522-1531

  • DOI: 10.1016/j.bmcl.2019.04.008
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor ...

    Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC 50 's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).


    Organizational Affiliation

    Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China.,Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom.,Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.,Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: mzak@gene.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase JAK1
A
302Homo sapiensMutation(s): 0 
Gene Names: JAK1 (JAK1A, JAK1B)
EC: 2.7.10.2
Find proteins for P23458 (Homo sapiens)
Go to Gene View: JAK1
Go to UniProtKB:  P23458
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
A
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
KES
Query on KES

Download SDF File 
Download CCD File 
A
N-{5-[5-chloro-2-(difluoromethoxy)phenyl]-1H-pyrazol-4-yl}pyrazolo[1,5-a]pyrimidine-3-carboxamide
C17 H11 Cl F2 N6 O2
KHCFKCPXXJQHMH-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
A
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.224 
  • Space Group: P 2 21 21
Unit Cell:
Length (Å)Angle (°)
a = 44.830α = 90.00
b = 169.910β = 90.00
c = 42.710γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
xia2data reduction
Aimlessdata scaling
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2019-04-24
    Type: Initial release
  • Version 1.1: 2019-05-15
    Type: Data collection, Database references